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Abstract 
Vector control is a task previously relegated to products that (a) kill the mosquitoes directly at different stages (insec-
ticides, larvicides, baited traps), or (b) avoid/reduce human-mosquito contact (bed nets, repellents, house screening), 
thereby reducing transmission. The potential community-based administration of the endectocide ivermectin with 
the intent to kill mosquitoes that bite humans, and thus reduce malaria transmission, offers a novel approach using 
a well-known drug, but additional steps are required to address technical, regulatory and policy gaps. The proposed 
community administration of this drug presents dual novel paradigms; first, indirect impact on the community rather 
than on individuals, and second, the use of a drug for vector control. In this paper, the main questions related to the 
regulatory and policy pathways for such an application are identified. Succinct answers are proposed for how the 
efficacy, safety, acceptability, cost-effectiveness and programmatic suitability could result in regulatory approval and 
ultimately policy recommendations on the use of ivermectin as a complementary vector control tool.
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Background
One key goal of research on the use of ivermectin to 
reduce malaria transmission is documentation of the 
evidence required to support recommendation by the 
National Malaria Control Programmes (NMCP). Clearly, 
both safety and efficacy (defined as public health impact) 
would need to be established. There are, however, addi-
tional knowledge gaps that would need to be resolved to 
support regulatory approval and a World Health Organi-
zation (WHO) policy recommendation. This third paper 
of the thematic series reviews the main knowledge gaps 
in these key aspects.
Regulatory pathways
Current regulatory approval status
The current ivermectin oral formulation has FDA 
approval for the treatment of strongyloidiasis (200 mcg/
kg single dose) and for the treatment/control of oncho-
cerciasis in mass-distribution campaigns (150  mcg/kg 
one to four times a year) [1]. Ivermectin is additionally 
approved for the treatment of head lice [2] and rosacea 
[3] as topical formulations.
The French regulatory authorities have approved iver-
mectin for treatment of the microfilaraemia caused by 
Wuchereria bancrofti (150–200  mcg/kg twice a year or 
300–400 mcg/kg once a year), strongyloidiasis (200 mcg/
kg single dose) and scabies (200  mcg/kg once or twice 
in a 2-week period) [4]. In addition to onchocerciasis 
and strongyloidiasis, the Australian Therapeutic Drugs 
Administration has approved oral ivermectin for the 
treatment scabies (200 mcg/kg, two doses), and the Aus-
tralian label specifies that in cases of moderate to severe 
crusted scabies, “more than 3 doses may be required” [5].
Precedents for interventions that reduce malaria 
transmission and provide a delayed personal benefit
When used for the treatment of specific diseases such as 
onchocerciasis, lymphatic filariasis, or in the context of 
efforts aiming at eliminating these Neglected Tropical 
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Diseases (NTDs), ivermectin provides individuals with a 
direct benefit by reducing their personal parasite burden. 
It also lowers transmission of NTDs by reducing the par-
asite burden at community level; this can be seen as an 
additional indirect benefit for the individuals.
Up till recently, the discussion of ivermectin as a tool 
for malaria had focused exclusively on the potential for 
indirect benefit. However, there is now limited mouse 
model data on the potential of ivermectin to directly 
affect the liver stages of the Plasmodium parasite [6, 
7], yet the mechanism of action is poorly understood. 
There has not been specific evaluation of the potential 
for a direct effect of ivermectin on human Plasmodium, 
although some field data suggest this might be the case 
[8]. Should it prove to have a direct effect on the malaria 
parasite, additional regulatory discussions would be 
needed and possibly be lengthy. These early data, how-
ever, suggest that the effect is partial and thus would be a 
non-primary endpoint, for which label indication would 
not be sought.
Therefore, for the purpose of this paper, it is assumed 
that ivermectin mass drug administration (MDA) would 
reduce malaria transmission at a community level, but 
healthy individuals would not receive a personal direct 
benefit from the drug, with the exception being those 
with susceptible NTDs. There are at least two precedents 
for such an intervention:
Low dose primaquine as gametocytocide
The use of low dose primaquine, together with a course 
of artemisinin-based combination therapy (ACT), has 
been recommended by the WHO to reduce transmission 
in low-transmission areas via its gametocytocidal effect 
on Plasmodium falciparum [9], even in the absence of 
prophylactic effect or activity against asexual parasites. 
The recommendation is based on its safety at the recom-
mended dose and on the expected population benefit 
obtained by the transmission-blocking effect, particularly 
in areas threatened by artemisinin resistance.
Transmission‑blocking vaccines. The work of PATH Malaria 
Vaccine Initiative (MVI)
In 2010, PATH MVI hosted a workshop to explore the 
possibility of including transmission-blocking vaccines in 
strategies towards malaria elimination; it focused on the 
clinical development and regulatory pathways for such 
a tool. The outcome of that workshop and the progress 
achieved since 2010 have been updated recently [10]. 
From the regulatory perspective, there are many parallels 
between the use of a transmission-blocking vaccine and 
the use of ivermectin for vector control. Here are some 
important conclusions that could be applicable to endec-
tocide use in humans [10]:
  • Transmission-blocking vaccines are seen as poten-
tial tools for accelerating to elimination and possibly, 
prevent re-introduction.
  • The US Food and Drug Administration has indicated 
that there is no legal bar to prevent the development 
of transmission-blocking interventions, but ethical 
review would be critical; that the proposed endpoint 
of a delayed personal benefit via a community effect 
is not a major obstacle for clinical development; 
and that there are two potential clinical develop-
ment pathways for transmission-blocking vaccines: 
a cluster randomized trial proving clinical benefits 
at community level, or approval based on biological 
surrogates of efficacy and confirmation of efficacy at 
community level post-approval.
  • There is need to standardize the assays and efficacy 
correlates for transmission-blocking vaccines.
  • The delayed personal benefit of transmission–block-
ing interventions should be the primary emphasis, 
rather than referring to these as “altruistic”.
  • Modelling may help define target efficacy early in 
the development process and provide insight on the 
public health benefit in different settings as the added 
benefit may not be the same in different scenarios.
  • Discussions on the manufacture, procurement and 
distribution for large/remote populations should be 
started early.
Key regulatory pathway points for the novel application 
of ivermectin
What is the most appropriate regulatory agency, given the 
overlap between pharmaceuticals (drug), vector control, 
and indirect impact on malaria?
The proposed use of the drug ivermectin to reduce 
malaria transmission by its mosquito-killing effect 
implies the mass administration of the drug to humans; 
hence, regulatory approval should come from the drug 
section of a human health agency. The FDA Center for 
Biologics has been conceptually supportive of a trans-
mission-blocking vaccine. Moreover, it has stated that 
it could rule on products not primarily intended to be 
marketed in the United States. It would also rule on 
products that would have a community effect leading to 
delayed personal benefit, a key obstacle for licensure for 
transmission-blocking vaccines [10]. There is no avail-
able data on the status on these discussions with the 
EMA, although it does have Article 58, which supports 
its offering an opinion on a product to be used primarily 
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in endemic areas outside of EMA’s primary geographic 
remit in collaboration with the WHO and relevant non-
EU regulatory authorities. Further discussion with both 
regulatory agencies by a potential sponsor would be 
required.
Potential regulatory pathway for ivermectin for malaria 
vector indication
If the goal is application for approval for novel use of 
the licensed product, then regulatory approval for drug 
repurposing could be sought via the 505(b)(2) pathway 
[11]. The 505(b)(2) has the advantage of allowing the use 
of evidence from studies not conducted by the sponsor, 
alleviating costs and reducing time to approval. An FDA 
draft guidance specifically for developing treatment and 
prophylactic products for malaria was drafted in 2007 
[12].
In any case, new tools and/or indications need to be 
proven effective [13] and safe [14]. For an ivermectin-
based vector control tool, the best clinical trial design to 
demonstrate both safety as well as public health impact 
on malaria transmission is a pivotal cluster randomized 
trial with sufficient power to assess both key endpoints. 
It should demonstrate added value on top of standard 
vector control tools, which should serve as the referent. 
As the impact and risk/benefit ratio of ivermectin MDA 
is expected to vary according to the baseline transmis-
sion, the selection of the scenario for the first study is key 
[15]. Note that this design was successfully utilized to 
definitely demonstrate the impact of other vector control 
tools, specifically LLINs [16].
For novel applications or new formulations, the FDA 
expedited approval process could be an option [17]. The 
FDA Expedited Approval Process aims to “facilitate and 
expedite development and review of new drugs to address 
unmet medical need in the treatment of a serious or life 
threatening condition (using) fast track designation, 
breakthrough therapy designation, accelerated approval, 
and priority review designation” [17]. For malaria elimi-
nation, both the challenges of residual transmission and 
insecticide resistance could meet the criterion on unmet 
medical need, and make ivermectin a good candidate for 
this approach. Further discussions with regulatory agen-
cies will be needed.
However, the accelerated approval scheme is based on 
the use of surrogate biological markers of efficacy [18]. 
In the case of ivermectin, the reduced survival seen in 
vectors feeding on treated subjects may be an appropri-
ate surrogate marker but is unlikely to lead to regulatory 
approval, much less policy recommendation and imple-
mentation at country level.
Key efficacy points for licensure
  – Key efficacy knowledge gaps were defined in the first 
paper of this thematic series [19].
  – The efficacy of any ivermectin-based regimen and indi-
cation is likely to depend on the baseline transmission 
intensity due to the nonlinear relationship between 
transmission and clinical malaria [20].
  – The efficacy will be a factor of the lethality and dura-
tion of effect (both directly related to the dose and for-
mulation used) [19].
  – A WHO statement would help define the target effi-
cacy considered to be of public health value. This 
would be followed by consensus and feedback from 
each regulatory agency. Importantly, the proportional 
importance of residual transmission in the pre-elim-
ination setting and the potential contribution of iver-
mectin as a tool should be considered.
Modelling to inform potential efficacy trial design and key 
parameters
Modelling will play a key role in the pre-licensure stage, 
when it can provide insight into the needed efficacy 
threshold to achieve certain goals in different transmis-
sion settings, i.e. interrupt transmission and suppress 
transmission by a target proportion. Additional factors 
that can be addressed by modelling include target pop-
ulation coverage, target blood levels, and their duration 
[21–23]. The risk–benefit assessment will vary according 
to the transmission scenarios.
Key efficacy question for regulatory purposes
In elimination campaigns through a high level of com-
munity MDA and existing vector control tools, does iver-
mectin add benefit, i.e. is it a valuable complementary 
vector strategy? If so by which mechanism? i.e. mosquito 
killing, partial prophylactic effect, others?
Ivermectin would reduce transmission by suppressing 
the vector population. It is envisaged as a complemen-
tary vector control strategy. Its “transmission-blocking” 
effect should not be compared with drugs that primarily 
reduce transmission from human-to-mosquito such as 
primaquine [15] as the impact of ivermectin is likely to be 
much higher. The primary outcome of studies assessing 
transmission-blocking drugs is normally the infectivity of 
humans to mosquitos as read by the presence of oocysts 
or sporozoites in mosquitoes fed on treated volunteers 
[24] while the primary outcome of studies assessing iver-
mectin and other endectocides in the insectary is usually 
mosquito survival. These are different but complemen-
tary strategies. The challenge for the malaria commu-
nity is generating the data that enables selection of the 
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most cost-effective strategy for varying strata of malaria 
endemicity.
Key safety points for licensure
Key knowledge gaps were defined in the first paper of this 
thematic series [19].
Ivermectin has been proven safe in MDA campaigns in 
the last 30 years, primarily in single dose campaigns dis-
tributed once or twice a year. However, its use in malaria 
is likely to include higher or more frequent doses which 
may affect the safety profile. There is some guidance on 
the cut-off points for severe adverse event for anti-malar-
ials intended to be used in MDA campaigns [25].
WHO prequalification
The WHO prequalification (WHO-PQ) process assures 
quality, safety, efficacy and suitability of priority medi-
cines for low and middle income countries [26]. The 
WHO-PQ scheme includes ivermectin among the drugs 
that can be prequalified for NTDs [27], yet to date no 
sponsor has submitted their ivermectin product for 
prequalification. This is likely because the drug used in 
Onchocerciasis and LF programmes country is donated 
by Merck [28], i.e. without financial support from funds 
like the Global Fund to Fight AIDS, Tuberculosis and 
Malaria (GFATM), hence the product does not require 
prequalification for its current MDA use. The mar-
ket price in the Europe is 18.44 euros for four tablets of 
3 mg [29], in the US the National Drug Acquisition Cost 
for  Stromectol® in January 2017 was 4.47 US dollars per 
each 3 mg tablet [30]. No price has been negotiated to the 
volume requirements for public sector procurement for 
malaria or NTD MDAs.
Policy pathway
The uptake of any ivermectin-based strategy by coun-
tries will depend on the presence of a clear WHO 
policy recommendation that is in turn supported by 
relevant evidence regarding efficacy and safety, as well 
as data on cost effectiveness, ethics, and community 
acceptance.
Role within WHO to assess the use of ivermectin for malaria
Once consensus on settings, comparators and outcome 
measures of new trials has been reached, evidence would 
likely be evaluated by the Malaria Policy Advisory Com-
mittee (MPAC) of the Global Malaria Programme at 
WHO. Given the geographic and disease overlaps, the 
interface between the malaria and NTD programmes 
will play an important role, and there are precedents for 
cross-WHO coordination to guide and evaluate product 
development and policy recommendations.
Refining the evidence needed for a WHO policy 
recommendation
It will be important to align the development of any 
ivermectin-based tool with the unique requirements 
of health systems of the endemic countries in which it 
would be used [31]. The type of evidence required during 
the WHO policy development process has been reviewed 
by Milstien et  al. based on the introduction of malaria 
intermittent preventive treatment in infancy (IPTi) and 
four relatively recent vaccines as a case study for new 
malaria vaccines [32]. Their conclusions were used as 
guidance for the present section. The evidence needed 
for a policy recommendation can be classified in four 
main categories: efficacy, safety, feasibility and cost-effec-
tiveness. Given the particular nature of an ivermectin-
based tool to reduce malaria transmission, the category 
acceptability is also included here.
Key policy questions
Recommendation of ivermectin will be based on proven 
efficacy, safety, cost-effectiveness and feasibility for the 
geographies and populations where it would be used. Piv-
otal questions related to these four aspects are posed and 
answered below.
Efficacy
(i) Is there evidence of  an acceptable level of  reduction 
of  morbidity and/or mortality in  the target popula‑
tions? Using transmission-blocking vaccines as a proxy, 
“there is currently no clinical trial data available to deter-
mine the efficacy threshold that would be required to have 
a clinically beneficial impact on transmission and achieve 
elimination” [20]. What is considered an “acceptable” effi-
cacy threshold for ivermectin must be estimated with the 
help of modelling and validated with empirical data dur-
ing clinical trials? At a minimum, this must be statistically 
different than the referent (standard vector control and 
case management) in a well-designed, sufficiently-pow-
ered trial, but it should also be of public health relevance. 
Of note, given the mandate of providing population at risk 
with either LLINs or IRS any ivermectin MDA trial would 
be assessing the superiority of the combination which will 
require larger trial size. This incremental impact will be 
considered differently depending on the settings. Various 
epidemiological settings should be tested with priority 
given to pre-elimination settings where additional new 
tools are needed to cover the last mile to elimination.
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(ii) Is the efficacy demonstrated in  different malaria 
endemicity levels? Different scenarios for the use of 
ivermectin to reduce malaria transmission have been 
considered [15], reflecting the variety of malaria ende-
micity conditions and elimination scenarios in which it 
will be used. It is possible that the dosage/dosing regi-
men combinations will need to be optimized to different 
scenarios. All scenarios cannot possibly be tested prior 
to recommendation, but a relevant strategy (dose and 
regimen) could be based on current approaches to MDA 
(3-day regimes) or, perhaps, an expansion of seasonal 
dosing schemes such as seasonal malaria chemoprophy-
laxis (SMC), although this last approach would require 
adaptation to include all ages rather than just children 
and drug–drug interaction studies with SMC drugs. An 
initial approach to the upper limit of ivermectin dose 
could be based on the cumulative dose recommended 
to patients with severe crusted scabies (up to seven 
200 mcg/kg doses in a month) [33].
(iii) Should the use of an endectocide other than ivermec‑
tin be considered? Other existing endectocides tested as 
mosquitocidal drugs include eprinomectin, selamectin, 
moxidectin (all available as systemic insecticides for lifes-
tock) [34], spinosad and nitenpyram (available as systemic 
insecticides for companion animals) [34] and fipronil 
(available as a spot-on for companion animals but used 
systemically under experimental conditions) [35].
Some of the advantages of these alternatives include:
  • Primarily the possibility of selecting preclinical can-
didates with considerably longer half-life.
  • Possibly reducing concerns about increasing selec-
tive pressure on onchocerciasis and soil-transmitted 
helminths by using the ones with different mode of 
action.
  • Some of the tested endectocides are effective against 
Aedes mosquitoes, which makes them attractive for 
the control of arboviruses. Ivermectin is not effective 
against Aedes mosquitoes at physiologically relevant 
concentrations.
Some disadvantages include:
  • Most alternatives are early in development, and 
thus their safety profile in humans would need to 
be established. Development of any of these drugs 
would require extensive toxicological and clinical 
testing both for safety and efficacy. This would be a 
longer and costly development pathway that could be 
pursued in parallel with ivermectin.
  • Unknown efficacy of new compounds on NTDs.
Safety
(i) Is the safety profile acceptable? In the absence of Loa 
loa co-endemicity, MDA programmes for onchocerciasis 
control report no severe adverse reactions to ivermectin 
and their rate of moderate adverse reactions is ≤1.3% [36]. 
These include ocular irritation, pruritus, rash, pain (gen-
eral, lymph nodes, headache and joints), dizziness, weak-
ness, fever, ocular irritation, nausea and diarrhoea [36]. In 
individuals with a high Loa burden (above 30,000 mf/ml) 
there is risk of severe adverse event including fata enceph-
alopathy. Such high worm loads are more normally asso-
ciated with areas of high prevalence which are normally 
avoided by ivermectin MDA campaigns [37]. However 
novel screening tools may allow a precise exclusion based 
on individual risk [38].
(ii) Is there significant adverse impact on  other malaria 
prevention and  treatment strategies? This could occur 
through interaction of ivermectin and anti-malarials and 
should be addressed during development, particularly 
with ACT and HIV/TB drugs by means of pharmacoki-
netic studies [19].
(iii) What is the safety profile in  immunologically com‑
promised groups, i.e. HIV‑infected? Ivermectin can be 
used to treat crusted scabies and strongyloidiasis in HIV-
positive patients. During MDA, individuals are not strati-
fied according to their serological status; only pregnant 
women, lactating women in the first week after birth, 
children <90 cm in height (approximately 15 kg) and the 
severely ill are systematically excluded [39]. The safety 
questions in high risk groups will be related to the new 
dose and dosing schemes proposed that are the same as 
the rest of the population.
Acceptability
(i) Would an “only” transmission‑blocking intervention 
be acceptable? The reduction in malaria transmission 
achieved through ivermectin would mostly derive from 
mosquito mortality [22], hence ivermectin should be 
seen as a new paradigm of vector control, as opposed to 
a transmission-blocking drug that would treat malaria 
and also decrease transmission [15]. Moreover, as cur-
rently envisioned, ivermectin is not a stand-alone tool, 
but rather a complementary vector control strategy to be 
added to the emerging elimination strategy. Finally, the 
use of ivermectin will provide personal benefit in terms of 
NTDs and ectoparasites. The caveat is animal studies that 
indicate a direct of effect of ivermectin on Plasmodium 
liver stages [6, 7]. This is preliminary, intriguing and needs 
to be better understood, in terms of mechanism and pos-
sible effect in humans.
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(ii) Potential consequences of  malaria ivermectin MDA 
for NTD programmes Ivermectin is the drug of choice 
for the treatment of onchocerciasis. It is also the only 
drug used in campaigns aimed at eliminating onchocer-
ciasis. In Africa alone, the overlap between onchocercia-
sis [40] and malaria endemicity [41] is practically 100% 
as shown in Fig. 1. An increase frequency in the admin-
istration of ivermectin (as could be expected if used for 
malaria) could shorten the time to interrupt transmis-
sion of onchocerciasis in certain settings [42] and has 
been previously advocated as a necessary measure in 
areas where interruption of transmission has not been 
achieved after 10 years of annual treatment [43]. If there 
is potential to shorten the time during which ivermectin 
donation is needed, this could have profound implica-
tions for the business model used today. Moreover, iver-
mectin has also been demonstrated, in a triple combina-
tion, to have remarkable potential impact on elimination 
lymphatic filariasis [44].
While the single dose used for each of these diseases 
is not sufficient for impact on malaria, distribution for 
malaria indication should suffice as a dose for either dis-
ease, so careful coordination between malaria and NTD 
communities would result in most efficient use of sup-
ply. Additionally, ivermectin has at least partial activity 
against several soil-transmitted helminths and ectopara-
sites, it is reasonable to expect benefit in this context in 
communities where an ivermectin-based tool for malaria 
is implemented [45].
This potential tool will optimally require collaboration 
between the malaria and NTD programmes, including 
joint research efforts. Two examples or effective collabo-
ration could be:
  • Data sharing at programme level to optimize timing 
of ivermectin distribution for malaria and increase 
impact (dry vs rainy season) and avoid unnecessary 
duplication of NTD programmes.
  • Ivermectin distribution for malaria with the co-
administrations [46, 47] needed as an NTD interven-
tion.
There have been concerns about increasing selec-
tive pressure on soil-transmitted helminths and filariae 
with a wider use of ivermectin. There is limited data on 
this possibility. Previous reports of ivermectin-resistant 
Onchocerca [48] have been the subject of debate [49–52]. 
The drug has in fact been used for decades with excellent 
results in reducing NTD transmission. Additionally, if 
used in malaria elimination efforts the number of MDA 
rounds will be limited. There is previous positive expe-
rience on the impact of malaria interventions on NTD 
transmission such as the possibility to halt LF transmis-
sion by scaling up LLINs in Nigeria [53].
Fig. 1 Overlap between selected onchocerciasis and malaria endemic areas in Africa. a Estimated prevalence of palpable Onchocerca nodules in 
the 20 African Programme for Onchocerciasis Control countries in 2011 as described by Zouré and colleagues [41]. b Plasmodium falciparum para-
site rate in 2–10 years old in 2015 as described by Bhatt and colleagues [42]
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There is increasing interest in the potential use of Mox-
idectin for onchocerciasis [54], having a second drug 
available for onchocerciasis might help manage resist-
ance concerns. However, given the similarities in molec-
ular structure and mode of action [55] there is potential 
for co-resistance [56]. The lethal concentration 50 of 
moxidectin for Anopheles mosquitoes [34] is one order 
of magnitude above the Cmax reached using maximum 
moxidectin doses in humans [57]. In the meantime, iver-
mectin remains the sole drug for the control and elimi-
nation of onchocerciasis and an important pillar for the 
treatment of lymphatic filariasis.
An additional potential risk is diverting the drug supply 
away from NTD programmes. Yet this is also an oppor-
tunity. A novel indication for malaria would increase 
market and demand, which should serve as incentive for 
manufacturers to go through the WHO-PQ process.
(iv) What are the expected compliance and  adherence? 
And  how could they influence effectiveness? Effective-
ness will be directly related to coverage. Coverage in turn 
can be greatly influenced by compliance and adherence. 
Complex and prolonged dosing schemes can negatively 
impact both [58, 59]. This aspect should be evaluated early 
through appropriate acceptability studies and addressed 
by identifying the shortest regimen necessary to have sig-
nificant impact on malaria transmission.
Use of resources
Thus far, more than 2.7  billion doses of ivermectin have 
been donated and used by involved countries in Africa, 
Asia and Latin America, administered to more than 
80 million people annually and with no cost for commodi-
ties to the public sector. The business model of the Mecti-
zan Donation Programme was expanded in 2010 with the 
commitment of several pharmaceutical companies, along 
with NGOs, government agencies and academia to sustain, 
extend and expand the programmes to ensure the neces-
sary supply of donated drugs to help control and eliminate 
NTDs [60]. The implication of this business model for 
ivermectin supply for malaria remains to be worked out as 
there is no commitment for donating the drug for this pur-
pose. New manufacturers are needed to ensure supply for 
malaria and NTD elimination, and the public sector will 
need to understand the cost of goods at scale, to best nego-
tiate of supply and price for malaria programmes.
The WHO guidelines for cost-effectiveness analysis of 
vector control were issued in 1993 and are now archived 
[61]. Four basic questions are proposed here, the com-
ments on each question reflect the available data at this 
time.
(i) What are the expected costs of  protection per  per‑
son? The median financial costs of protecting one per-
son for one year with core vector control interventions 
have been estimated in US$ 2.20 (0.88–9.54) for insec-
ticide treated nets and US$ 6.70 (2.22–12.85) for indoor 
residual spraying [62]. The most important factor affect-
ing cost of goods for drugs is the clinically effective dose 
in patients [25]. Ivermectin has the advantage of being 
effective at low doses (µg/kg), which can reduce costs in 
comparison with drugs needing doses in the grams range. 
In the context of the Mectizan Donation Programme, the 
value for donation of one tablet of ivermectin has been 
calculated at US$ 1.50 [63]. The purchase price in con-
text of large scale purchase for public sector purchase 
for malaria MDA will likely be much lower. Ivermectin is 
off-patent since 1996 and apart from Merck, is available 
from several generic manufacturers [64], although none 
of these are yet prequalified by WHO.
The programmatic costs of MDA for onchocercia-
sis and lymphatic filariasis vary according to geography 
as well as the method chosen for distribution (passive, 
community-based, community-directed, national mobile 
teams) [65].
The fact that the efficacy of ivermectin is directly 
related to blood concentrations and their duration, its 
small dose per body weight and its lipophilic nature 
makes it a good candidate for single-dose, slow-release 
formulations that can be used to achieve longer term 
benefits and further reduce costs [23, 25], once develop-
ment is completed. Once consensus is reached on can-
didate doses and formulations, packaging discussions 
should start early as they can greatly influence compli-
ance, costs and programmatic suitability [66].
(ii) What financing discussions are needed? There are 
important data gaps on what the cost of goods of iver-
mectin at scale for malaria would be. The upper boundary 
should be the calculated U.S. donation value for NTDs of 
US$ 1.5 per 3 mg tablet 1.50 [63], the real price however 
should be negotiated. The economic benefits of ivermec-
tin distribution for onchocerciasis are partly based on a 
donated drug. The value of this donated drug may surpass 
the operational budgets of the control programmes and 
the economic benefits expected from them for the next 
20  years [64]. Given the higher burden and economic 
costs related to malaria and expected price negotiations, 
this balance might be more positive, especially in the con-
text of elimination.
An important economic discussion would be the possi-
bility for any new ivermectin-based tool to be financed by 
the GFATM in case it is included in a country plan, and 
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recommended by WHO. WHO prequalification of the 
new indication for malaria or any new formulation will 
be a prerequisite for policy recommendation and thus 
GFATM financing.
Supply
(i) Is the manufacture process scalable? Ivermectin is 
semi-synthetic derivate of a bacterial bio product [67]. 
The manufacturing process is technically scalable. As 
the global demand increased, its production has been 
enhanced and purified by a number of methods [68, 
69]. The current global production is above 150  tons of 
active pharmaceutical ingredient per year (estimate from 
the Argentinian Chamber of Veterinary Products, pers. 
comm.), most of it is for veterinary use. As guidance, 
only 2.24  tons per year are needed to treat 80  million 
people, the target of the Mectizan Donation Programme 
(assuming an average weight of 70 kg, at the 200 µg/kg-
dose, twice a year); that is less than 1.5% of the current 
global production. Even a tenfold increase on the global 
demand for human use, due to its theoretical application 
in malaria control would represent less than 15% of the 
current production due to the co-endemicity of oncho-
cerciasis and malaria in many regions. Note that malaria 
use would likely be phased in over time.
Here it is important to distinguish between the pro-
duction of the API (which would be the main limiting 
step where there an increase in the global demand due 
to malaria use), and the manufacturer of final products. 
There are dozens of large scale API producers, mainly in 
china with some of them reporting an annual production 
above 50  tons (see Additional file  1). The API used for 
veterinary and human products can come from the same 
source but must fulfil different quality standards which 
might require additional purification steps. Although 
there are several hundred manufacturers of final product 
(see for example [70] for a list with more than 100 generic 
products and manufacturers only in India), the produc-
tion output and technical capacity of these manufactur-
ers to obtain WHO-PQ will play a key role on ultimately 
fulfilling the global demand.
(ii) Current and prospective global demand for NTDs More 
than 200 million doses were donated for the control and 
eradication of onchocerciasis and lymphatic filariasis in 
2015 [28]. The demand will vary according to the opera-
tional goals for onchocerciasis (control, elimination or 
eradication). One estimate is it could reach up to 2.63 bil-
lion treatments for the 2013–2045 period [71], but higher 
demand due to accelerated LF elimination with drug combo 
strategies can be expected [44, 47].
(iii) What would be the Go/No‑Go criteria for the develop‑
ment of new formulations or novel dosing schemes? The 
efficacy threshold is expected to be in direct relationship 
with the total dose and the area under the curve [15]. The 
safety and programmatic feasibility of schemes requir-
ing high or multiple doses should be measured against 
the expected efficacy. Novel formulations could simplify 
the dosing schemes and increase compliance but would 
require R&D investment.
A note on roles and sequence
This paper looks at the potential use of ivermectin for 
malaria from a regulatory and policy point perspective. 
Several key steps needed to fill these gaps have been 
identified. There are specific actors associated with some 
activities, for example prequalification can only come 
from the WHO-PQ team. Other activities have a broader 
range of potential actors, for example, there are several 
first tier regulatory authorities qualified to review this 
approach (EMA, FDA, TGA…). Although some concrete 
actor-action pairs have been mentioned in the corre-
sponding section of this paper, including redundant lists 
of potentially involved institutions or committees at each 
step has been avoided.
There is clear need for a regulatory sponsor to drive 
this forward on the global health stage. This gap could be 
filled by a producer interested in the potential novel mar-
ket, a consortium interested in filling the knowledge gaps 
or an NGO focused on global health.
The series of concrete actions ultimately leading to 
implementation have been discussed in two distinct 
sections, regulatory and policy. This division has been 
introduced to facilitate the discussion of each particular 
action, yet the separation is artificial as there are cross-
cutting issues related to both pathways. Additionally, 
it would be a very complex task to try to provide a par-
ticular order in which these actions should be followed. 
It is clear for example that regulatory approval can only 
follow evidence on efficacy and safety, other points like 
WHO-PQ for example, would require discussions related 
to programmatic suitability and technical capacity of 
producers from early on in the development process. Fig-
ure  2 is not intended as a technical guidance for a par-
ticular order, but illustrates how several processes are 
related and could happen in parallel.
Conclusions
Implementation of an ivermectin-based strategy to 
reduce malaria transmission will require higher or more 
frequent doses that currently used for NTDs. Efficacy 
and safety will be the most important parameters to be 
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evaluated by any stringent regulatory authority; both are 
directly related to the dose and dosing scheme selected 
for malaria. For a WHO policy recommendation, addi-
tional factors such as cost-effectiveness, acceptability and 
programmatic suitability will need to be addressed.
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